The heated debate on the risk-benefit balance of electronic cigarettes continues unabated. Nearly 20 years after its invention, vaping remains divisive among health authorities worldwide. Both proponents and critics present compelling arguments regarding heated e-liquids. Here's a balanced breakdown grounded in expert analyses.
Two decades on, France's Ministry of Health has yet to approve e-cigarettes as a smoking cessation aid, despite decades of anti-tobacco campaigns aimed at shedding the nation's "Europe's Chimney" reputation. Key concerns include insufficient long-term data on vaping's health impacts and fears it could initiate smoking among youth, lured by appealing flavors from manufacturers.
Advocates for a "harm reduction" approach offer strong evidence. A Public Health France study from June 26, 2019 (as reported in Le Figaro), credits e-cigarettes with helping 700,000 French smokers quit between 2012 and 2019—outperforming traditional nicotine replacements like patches and gums. The National Academy of Medicine endorses vaping empirically for quitting, while the more reserved Haute Autorité de Santé (HAS) neither recommends nor discourages it for motivated smokers.
Health experts united against vaping outside cessation contexts agree: e-cigarettes should only support smokers in significantly reducing or quitting tobacco. Dual use without drastic cuts risks worsening addiction. Thus, non-smokers should never view vaping recreationally. Opponents of flavored e-liquids argue only tobacco flavors are appropriate—to ease weaning without enticing flavor experimentation.
Though not in its official anti-smoking toolkit—relying on campaigns, reimbursable substitutes, rising cigarette prices, and public bans—the Ministry's rhetoric has softened. Its e-cigarette page notes: "1.1 to 1.9 million daily users in France; 67% are smokers using it to quit or cut consumption, potentially lowering health risks."
Traditional cigarettes' dangers stem mainly from tobacco combustion, releasing toxins like carbon monoxide, volatile organics (ketones, aldehydes, ammonia, hydrocarbons), tar (benzopyrenes, anthracenes), nitrates, heavy metals (cadmium), free radicals, and trace radioactives.
E-liquids, akin to tobacco in classic smokes, draw scrutiny. Assessing vaping requires comparing heated e-liquid risks to burned tobacco—always in context.
ANSES's comprehensive press kit confirms 75% of French-market e-liquids are locally or EU-made. Its exhaustive database reveals:
ANSES analyzes cold e-liquids; CRIVAPE's heated tests show mere micrograms of carcinogens per 200 puffs—far below AFNOR standards. Contrast: French smoking prevention data pegs formalin alone at 3 mg per pack. Tobacco smoke harbors thousands of chemicals, over 50 carcinogenic, with full composition unknown.
INRS deems propylene glycol—common in foods, meds, cosmetics—non-toxic. Thus, the National Academy of Medicine's harm reduction stance holds: switching spares users tar, CO, and more, even sans full nicotine quit.
A stark case: In September 2019, U.S. CDC reported severe lung illnesses linked to vaping, peaking in New York. By February 4, 2020, 2,758 EVALI cases and 64 deaths emerged—all with vaping history.
Investigations pinpointed adulterated e-liquids with THC (cannabis' key compound, legally gray in France since 2007) from informal sources. Vitamin E acetate also implicated. France's National Academy of Medicine (December 12, 2019) clarified: "Not vaping itself, but diversion via adulterated contents caused the U.S. outbreak."
This underscores traceability needs. ANSES's public database lists all authorized French e-liquids' compositions. Vapers must verify pre-purchase, as ANSES flags discrepancies—like excess emissions or nicotine.
Longitudinal studies falter: short durations (<2 years) and confounding ex-smoker histories obscure effects.
Some experts argue irrelevance: view e-cigarettes as temporary cessation tools toward nicotine-free life. Yet, could brief use trigger delayed effects?
